Continuous Glucose Monitoring Device

Ioannis Tomazos, PhD, MBA. Dr. Tomazos was appointed as the CEO of Biorasis Inc. in 2008. Dr. Tomazos received a Doctoral degree in Cellular Biology and a Masters in Business Administration in Marketing from the University of Connecticut (UCONN). In the school of business he worked as a consultant for three businesses in the State of Connecticut, as a research assistant at the Office of Technology Commercialization of UCONN and completed an internship at Well Point. He has several publications and patents.

Biorasis Inc is developing needle-implantable glucose and other bio-analyte biosensors for use in drug development research, as well as for human on-demand metabolic disease management. Our technology includes both a miniaturized (0.5 mm x 0.5 mm x 5 mm) sensor platform (equipped with power source, signal processors and wireless communication), as well as biocompatible coatings that enables functioning of sensors for a period of 3 months. The continuous monitoring of body bio-analytes is key in the diagnosis, prognosis and treatment of diseases, such as diabetes, atherosclerosis, liver and kidney abnormalities, etc.